• Je něco špatně v tomto záznamu ?

Prenylated flavonoid morusin protects against TNBS-induced colitis in rats

Z. Vochyánová, M. Pokorná, D. Rotrekl, V. Smékal, P. Fictum, P. Suchý, J. Gajdziok, K. Šmejkal, J. Hošek,

. 2017 ; 12 (8) : e0182464. [pub] 20170810

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016434

Grantová podpora
NV16-27522A MZ0 CEP - Centrální evidence projektů

Morusin is a prenylated flavonoid isolated from the root bark of Morus alba. Many studies have shown the ability of flavonoids to act as anti-inflammatory agents. The aim of this study was to evaluate the effect of morusin on experimentally colitis induced by 2,4,6-trinitrobenzensulfonic acid in Wistar rats and to compare it with sulfasalazine, a drug conventionally used in the treatment of inflammatory bowel disease. Morusin was administered by gavage at doses of 12.5, 25, or 50 mg/kg/day for five days. The colonic tissue was evaluated macroscopically, histologically, and by performing immunodetection and zymographic analysis to determine the levels of antioxidant enzymes [superoxide dismutase (SOD) and catalase (CAT)], interleukin (IL)-1β, and transforming growth factor (TGF)-β1 and the activities of matrix metalloproteinases (MMP) 2 and 9. The tissue damage scores were significantly reduced with increasing dose of morusin, however efficacy was not demonstrated at the highest dose. At the dose of 12.5 mg/kg, morusin exerted therapeutic effectivity similar to that of sulfasalazine (50 mg/kg). This was associated with significant reduction of TGF-β1 levels and MMP2 and MMP9 activities, and slight reduction of IL-1β. Our results suggest that morusin possesses therapeutic potential for the treatment of chronic inflammatory diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016434
003      
CZ-PrNML
005      
20180515103807.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0182464 $2 doi
035    __
$a (PubMed)28797051
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vochyánová, Zora $u Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
245    10
$a Prenylated flavonoid morusin protects against TNBS-induced colitis in rats / $c Z. Vochyánová, M. Pokorná, D. Rotrekl, V. Smékal, P. Fictum, P. Suchý, J. Gajdziok, K. Šmejkal, J. Hošek,
520    9_
$a Morusin is a prenylated flavonoid isolated from the root bark of Morus alba. Many studies have shown the ability of flavonoids to act as anti-inflammatory agents. The aim of this study was to evaluate the effect of morusin on experimentally colitis induced by 2,4,6-trinitrobenzensulfonic acid in Wistar rats and to compare it with sulfasalazine, a drug conventionally used in the treatment of inflammatory bowel disease. Morusin was administered by gavage at doses of 12.5, 25, or 50 mg/kg/day for five days. The colonic tissue was evaluated macroscopically, histologically, and by performing immunodetection and zymographic analysis to determine the levels of antioxidant enzymes [superoxide dismutase (SOD) and catalase (CAT)], interleukin (IL)-1β, and transforming growth factor (TGF)-β1 and the activities of matrix metalloproteinases (MMP) 2 and 9. The tissue damage scores were significantly reduced with increasing dose of morusin, however efficacy was not demonstrated at the highest dose. At the dose of 12.5 mg/kg, morusin exerted therapeutic effectivity similar to that of sulfasalazine (50 mg/kg). This was associated with significant reduction of TGF-β1 levels and MMP2 and MMP9 activities, and slight reduction of IL-1β. Our results suggest that morusin possesses therapeutic potential for the treatment of chronic inflammatory diseases.
650    _2
$a zvířata $7 D000818
650    _2
$a kolitida $x chemicky indukované $x enzymologie $x prevence a kontrola $7 D003092
650    _2
$a kolon $x účinky léků $x enzymologie $x patologie $7 D003106
650    _2
$a flavonoidy $x farmakologie $7 D005419
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a matrixová metaloproteinasa 2 $x metabolismus $7 D020778
650    _2
$a prenylace $7 D054876
650    _2
$a potkani Wistar $7 D017208
650    _2
$a kyselina trinitrobenzensulfonová $7 D014302
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pokorná, Marie $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Rotrekl, Dominik $u Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Smékal, Václav $u Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Fictum, Petr $u Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Suchý, Pavel $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Gajdziok, Jan $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Šmejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Hošek, Jan $u Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 8 (2017), s. e0182464
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28797051 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103941 $b ABA008
999    __
$a ok $b bmc $g 1300058 $s 1013274
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 8 $d e0182464 $e 20170810 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV16-27522A $p MZ0
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

    Možnosti archivace